Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer

Sembulingam Tamilzhalagan, Muthulakshmi Muthuswami, Jayaprakash Periasamy, Ming Hui Lee, SunYoung Rha, Patrick Tan, Kumaresan Ganesan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.

Original languageEnglish
Pages (from-to)1075-1086
Number of pages12
JournalCellular Signalling
Volume27
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Stomach Neoplasms
Genes
Neoplasm Genes
RNA Interference
Tumor Cell Line
Phosphatidylinositol 3-Kinases
Chromosome Aberrations
Stomach
Cell Cycle
Carcinogenesis
Cell Line
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cell Biology

Cite this

Tamilzhalagan, Sembulingam ; Muthuswami, Muthulakshmi ; Periasamy, Jayaprakash ; Lee, Ming Hui ; Rha, SunYoung ; Tan, Patrick ; Ganesan, Kumaresan. / Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. In: Cellular Signalling. 2015 ; Vol. 27, No. 6. pp. 1075-1086.
@article{31caf1ce963d4c16bf61006f8d32326d,
title = "Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer",
abstract = "Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10{\%} of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.",
author = "Sembulingam Tamilzhalagan and Muthulakshmi Muthuswami and Jayaprakash Periasamy and Lee, {Ming Hui} and SunYoung Rha and Patrick Tan and Kumaresan Ganesan",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.cellsig.2015.02.010",
language = "English",
volume = "27",
pages = "1075--1086",
journal = "Cellular Signalling",
issn = "0898-6568",
publisher = "Elsevier Inc.",
number = "6",

}

Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. / Tamilzhalagan, Sembulingam; Muthuswami, Muthulakshmi; Periasamy, Jayaprakash; Lee, Ming Hui; Rha, SunYoung; Tan, Patrick; Ganesan, Kumaresan.

In: Cellular Signalling, Vol. 27, No. 6, 01.06.2015, p. 1075-1086.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer

AU - Tamilzhalagan, Sembulingam

AU - Muthuswami, Muthulakshmi

AU - Periasamy, Jayaprakash

AU - Lee, Ming Hui

AU - Rha, SunYoung

AU - Tan, Patrick

AU - Ganesan, Kumaresan

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.

AB - Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84939972327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939972327&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2015.02.010

DO - 10.1016/j.cellsig.2015.02.010

M3 - Article

C2 - 25697906

AN - SCOPUS:84939972327

VL - 27

SP - 1075

EP - 1086

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

IS - 6

ER -